OmniAb (OABI) Insider Philip Gotwals Sells 20,000 Shares

Philip Gotwals sold 20,000 shares of OmniAb, Inc. (OABI) on June 17, 2026. The shares were sold at a market price of $2.34 each, bringing the total value to about $46,800. This transaction is part of ongoing insider activity at the company.

Inside Philip Gotwals' Trade

Gotwals' recent sale adds to a series of insider transactions at OmniAb. The 20,000 shares sold reflect his strategic moves as an insider but do not necessarily indicate a negative outlook on the company.

Other Institutional Activity in OmniAb

In the latest reporting period, institutional investors have been active with OmniAb's shares. Whitefort Capital Management, LP reduced its holdings by 3,975,711 shares, ending up with 10,248,658 shares valued at about $46.9 million. In contrast, BlackRock Inc. added 790,438 shares for a total of 8,897,490 shares worth approximately $40.7 million. Meanwhile, Nomura Holdings Inc. increased its stake by 4,323,116 shares, now holding 5,028,160 shares valued at around $23 million. Cadian Capital Management, LP saw a slight increase of 54,872 shares, totaling 4,211,821 shares worth about $19.3 million. Lastly, Vanguard Capital Management LLC trimmed its position by 141,378 shares, holding a total of 3,852,356 shares valued at approximately $17.6 million.

OmniAb, Inc. Stock Down 47.7%

As of June 30, 2026, OmniAb's shares trade at about $2.34, which is below its 50-day moving average of $3.38 and its previous close of $4.47. The stock remains significantly lower than its 52-week high of $5.43. This positioning may influence investor sentiment in the coming days.

Recent Earnings

OmniAb reported revenue of $38.5 million for the last quarter, reflecting a growth rate of 2.4%. However, the company faced a net margin of -1.15 and has an EPS of -0.36. Its next earnings report is scheduled for November 4, 2026.

Insider Buying and Selling at OmniAb, Inc.

On the same day as Gotwals' sale, other insiders also sold shares. Steven Love, Steven Crouse, and John Higgins each sold 20,000 shares. These transactions were not part of any planned trading strategy, showing a coordinated insider movement within the company.

Analysts Set New Price Targets

On October 7, 2026, Leerink Partners maintained an "Outperform" rating on OmniAb with a new price target of $12.00, up from $10.00. StoneX also maintained a "Buy" rating with a target increase from $4.00 to $6.00. HC Wainwright & Co. reiterated its "Buy" rating, keeping its price target at $11.00. The consensus among five analysts shows a mean price target of $8.4.

About OmniAb

OmniAb, Inc. is a biotechnology firm based in Emeryville, California. It focuses on providing discovery research technology to pharmaceutical and biotech companies, helping them develop therapeutic solutions. The company has a small workforce of 89 employees and is leveraging its unique technology platform across global markets, including the U.S., Europe, and Asia.

Bottom Line

Investors should watch for future insider activity and upcoming earnings on November 4, 2026. The recent trades by insiders, including Philip Gotwals, indicate a notable level of engagement. Remember, the Form 4 filings reflect past actions and may not represent current positions.